Streetbeat News

Revenues

RDY

Dr. Reddy's Laboratories has acquired MenoLabs, a company focused on women's health and dietary supplements. This acquisition expands Dr. Reddy's portfolio in the women's health space, potentially increasing its market share and revenue in this segment.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 11:02 am

AAPL

CALM

TSLA

UNF

U.S. stocks closed mostly lower on Tuesday, with the S&P 500 and Nasdaq Composite ending the session down. Apple Inc. shares dropped 3.6% after a Barclays downgrade, while Tesla Inc. reported increased vehicle production and deliveries in Q4. The CNN Money Fear and Greed index indicated a slight decline in market sentiment but remained in 'Extreme Greed' territory. Investors are looking forward to earnings from Cal-Maine Foods and UniFirst Corporation. The Dow Jones also closed lower, and economic data showed a dip in manufacturing PMI and a rise in construction spending.

Portfolio Pulse from Avi Kapoor

January 03, 2024 | 8:11 am

BYDDF

BYDDY

TSLA

BYD Co Ltd is rewarding its dealers with 2 billion yuan for meeting 2023 sales targets after outselling Tesla in Q4 global electric car sales. Dealers receive 666 yuan per vehicle sold. BYD's aggressive expansion and price cuts, along with securing a level 3 autonomous driving test license, aim to boost sales and maintain its lead over Tesla.

Portfolio Pulse from Benzinga Neuro

January 03, 2024 | 7:26 am

GTBIF

ITHUF

MMNFF

New York and New Jersey are at a regulatory crossroads with cannabis legalization, balancing social equity and industry growth. The New York Cannabis Control Board's tie vote on allowing medical marijuana companies like Green Thumb Industries and iAnthus Capital Holdings to enter the recreational market has left the decision pending. Meanwhile, MedMen Enterprises and Goodness Growth Holdings await similar consideration. New York approved two new cannabis testing labs and emphasized the need for more dispensaries. CONBUD, a social equity dispensary in New York, is a symbol of reform, owned by previously incarcerated individuals. New Jersey's cannabis market saw $578 million in sales, but faces challenges like high prices and local dispensary bans.

Portfolio Pulse from Joana Scopel

January 03, 2024 | 1:14 am

LMT

Lockheed Martin announced the delivery of 98 F-35s in 2023, increasing the global fleet to over 990 aircraft. The F-35s enhance the advanced 5th Generation capabilities and contribute to 21st Century Security deterrence for the U.S. and its allies.

Portfolio Pulse from Charles Gross

January 02, 2024 | 9:45 pm

XHR

Analysts have recently updated their ratings and price targets for Xenia Hotels & Resorts (NYSE:XHR), with a mix of opinions ranging from bullish to bearish. Over the last three months, there have been changes in sentiment, with the current average 12-month price target set at $13.5, up from the previous $13.25. Analysts from Jefferies, Wells Fargo, Keybanc, and Morgan Stanley have adjusted their ratings and price targets, reflecting their views on the company's market dynamics and performance. Xenia Hotels & Resorts is a REIT focusing on upscale hotels in the U.S., but it faces challenges with revenue decline, below-average net margin, ROE, and ROA, although it has a healthier debt-to-equity ratio compared to the industry.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:01 pm

WLK

Westlake (NYSE:WLK) received mixed analyst ratings over the past three months, with no change in the last 30 days. The average 12-month price target is $140.5, slightly down from $140.75. UBS, Piper Sandler, and B of A Securities have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Westlake's financials show a negative revenue trend with a -21.26% growth, but strong profitability with a net margin of 9.09% and above-average ROE and ROA. The company has a lower than industry average debt-to-equity ratio of 0.5.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:01 pm

SMTC

In the last three months, 6 analysts have provided diverse ratings for Semtech (NASDAQ:SMTC), with a shift towards a more bearish sentiment. The average 12-month price target has been reduced by 9.24%, with a current average of $28.5. Analysts from firms like Stifel, Roth MKM, Needham, Susquehanna, and Benchmark have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Semtech's financials show a positive revenue trend but challenges in net margin, ROE, ROA, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:01 pm

PATH

UiPath (NYSE:PATH) received 9 analyst ratings in the last quarter with a spectrum of views. The average 12-month price target is $22.0, up 17.33% from the previous $18.75. Analysts from firms like Canaccord Genuity, JP Morgan, and RBC Capital have raised their price targets, reflecting optimism about the company's prospects. UiPath's financial health shows strong revenue growth but below-average profitability and efficiency metrics. The company's market capitalization is below the industry average, and it has a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:00 pm

SPT

Sprout Social (NASDAQ:SPT) has been reviewed by 4 analysts, with all maintaining a 'Somewhat Bullish' stance and raising their 12-month price targets, averaging $68.00, up from the previous $55.33. The company shows strong revenue growth but struggles with profitability and efficiency, as indicated by a net margin of -26.91% and ROA of -6.35%. The firm's market cap is above industry average, and it has a conservative debt-to-equity ratio of 0.65.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:00 pm